Ropes & Gray represented pharmaceutical company Amarin Corporation plc in an agreement with CSL Seqirus for an exclusive license and distribution agreement under which Amarin will license exclusive rights to cardiovascular medicine VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand. The transaction was announced on February 28.
Under the agreement, CSL Seqirus will in-license VAZKEPA from Amarin and will be responsible for market access and reimbursement efforts, distribution and commercial promotion for VAZKEPA across Australia and New Zealand. Amarin will receive an upfront payment and be eligible for event-related and product-related milestone payments. Amarin will be responsible for supplying finished product to CSL Seqirus.
The Ropes & Gray team included life sciences licensing partner Abigail Gregor.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.